BioVersys

BioVersys and partners are pleased to share the publication of AlpE data in #NatureCommunications. Read more: ir.bioversys.com/investor-relat… #GSK @univ_lille @PasteurLille #tuberculosis #antimicrobialresistance #globalhealth #biotech #drugdevelopment

#BioVersys announces that it has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health. ir.bioversys.com/investor-relat… @HMHNewJersey @UMNews #HealthCareInnovation #Collaboration #AMR #Antibiotics #InfectiousDiseases

📡 BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start. See: linkedin.com/posts/bioversy… #SavingLivesInResistantTimes #HealthcareInnovation #AMR #biotech #antibiotics #CRAB

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis. linkedin.com/posts/bioversy… @GSK @IHIEurope @UNITE4TB @EFPIA Deutsches Zentrum für Infektionsforschung (#DZIF), @LMU_Muenchen German Federal Ministry of Education and Research

📡 Meet BioVersys at the world renowned Gordon Research Conference, on New Antibacterial Discovery and Development on March 8-13, Lucca, Italy, to talk about our TB program in Phase 2. linkedin.com/feed/update/ur… @EDCTP @GSK @taskapplied @IHIEurope @univ_lille @PasteurLille

Cutting-edge clinical development is in focus, starting with a new combination targeting A. baumannii, we'll move onto novel approaches addressing chlamydia infections and a brand-new antibiotic for treating UTIs. 🎥 Watch live now: portalapp.bsac.eventsair.com/VirtualAttende… #ACC2026 #AMR

🚀🔬Day 2 kicks off with Session Five at #ACC2026 Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice. 🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAttende… @Bioversys I @SSI_dk I @GSK #AMR #ClinicalDevelopment

BioVersys — Poised to unlock value in critical AMR BioVersys is focused on developing novel drugs to address antimicrobial resistance (AMR)… @Bioversys $BIOV 📖 Full analysis: edisongroup.com/research/poise…

📡 BioVersys and partners’ Phase 2a tuberculosis trial results published in New England Journal of Medicine @EDCTP @GSK @taskapplied @bEtoTB1 @NEJM linkedin.com/feed/update/ur…

From @ETH lab to @sixgroup Swiss Exchange: the @Bioversys antibiotic revolution 🧬 top100startups.swiss/BioVersys-A-Jo… From an ETH Zürich spin-off to a publicly listed biotech tackling antibiotic resistance, BioVersys AG exemplifies how Swiss science can transform global health. With CHF 130 million raised, two WHO-priority drug candidates, and a CHF 213 million valuation on the SIX Swiss Exchange, the company is redefining the future of antibiotics. 💊 🗣️ As Founder & CEO Marc Gitzinger shares: “A world without access to working antibiotics would lead to losing the last 50 years of medical progress.” Supported by @venturekick and Venture Leaders by Venturelab, BioVersys AG’s journey from a PhD project to clinical breakthroughs and global partnerships, shows the power of persistence, precision, and purpose in biotech innovation. 💡 Read how BioVersys is rebuilding the antibiotic pipeline and leading the charge against resistant bacteria. Make sure to follow @venturekick to stay up to date on the latest breakthroughs, and discover the early-stage Swiss startups shaping the future of innovation! #TOP100SSU #SwissStartups #Innovation #Entrepreneurship #StartupEcosystem

🚀More exciting progress and success in funding BioVersys programs - with BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. Link to full press release: bit.ly/43PB1Go

📡 @Bioversys and @SHIONOGI_JP, enter into Global Research Collaboration for broad-spectrum NTM clinical candidates. Read more here: linkedin.com/feed/update/ur…

Click lifescievents.com/event/bioversy… for an informative KOL event; May 7, 2025, 8:30 AM ET / 2:30PM CEST. Featuring Professor David Paterson & Dr. Andrew Shorr, MD, discussing the unmet need & current treatment landscape for carbapenem resistant Acinetobacter baumannii pneumonia. #AMR

BioVersys announces joining the @AMRAccelerator EU-funded programme @RespiriNTM, access to up to €2 m in non-dilutive funding for our broad-spectrum NTM project. Read the full press release here: bioversys.com/?p=5519 #SavingLivesinResistantTimes #AMR #investment #Innovation

📡 Exciting times as BioVersys announces last patient, last visit in the Phase 2 clinical trial with BV100 showing positive first signs of efficacy for #VABP #CRAB. 🎯🌍 🏥 🚀 Read the full press release here: bioversys.com/?p=5490 #SavingLivesinResistantTimes #AMR #Innovation

BioVersys announces strategic investment from GIBF2 and launch of BV100 clinical program in China. · GIBF2 to invest US$ 6m in BioVersys · BV100 Phase 1 study in China expected to start in 1H 2025 Press release: bioversys.com/5454-2/ #AMR #investment #China #Innovation

🤝 We are excited to collaborate with @lifearc1, @MedDiscCat and @cftrust to expedite BioVersys’ NTM program to address serious infections in people living with CF.  💊 See PR with details: lnkd.in/gRiVDdux

@CFAMRSyndicate @MedDiscCat @cftrust @lifearc1 Thank you for posting this @CFAMRSyndicate (Twitter issues prevented us do so until now) - we are delighted to have joined forces with you to address resistant infections in people living with CF!

🎉 We're excited to announce that @Bioversys has been awarded with non-dilutive funding via our CDP programme to advance the pipeline of preclinical assets for CF lung infections. Read the press release ow.ly/rTUe50S8cEx @MedDiscCat | @cftrust | @lifearc1